Browse by category

A new approach to defining obesity could help physicians better determine which patients need more intensive treatment by focusing on the effects of excess adiposity on organs and tissues rather than relying primarily on whether a person meets a set of metabolic risk thresholds. Researchers from LSU's Pennington Biomedical Research Center examine the concept of "metabolically healthy obesity" and argue that a newer framework distinguishing preclinical obesity from clinical ob

Aqua Medical has announced the successful treatment of the first US patient in its FDA authorised Investigational Device Exemption (IDE) clinical trial evaluating the company's proprietary Proximal Intestinal Mucosal Ablation (PIMA) procedure for the treatment of type 2 diabetes. Aqua Medical is investigating a new diabetes procedure called proximal intestinal mucosal ablation (Illustration courtesy of Aqua Medical) Aqua Medical's investigational PIMA procedure utilises the c

Medtronic has presented its next-generation compute platform for the operating room. Touch Surgery Aide - an AI-native surgical computing platform that powers the Touch Surgery ecosystem - enables real-time artificial intelligence during procedures. Touch Surgery Aide was presented at the Society of Robotic Surgery (SRS) 2026 Annual Meeting in Florida. Touch Surgery Aide and the Touch Surgery ecosystem Built on years of experience, the Touch Surgery ecosystem brings insights

Johnson & Johnson has announced that the FDA has granted De Novo authorisation for its OTTAVA Robotic Surgical System, the world’s first table-integrated soft tissue robotic system. The system received marketing authorisation for multiple procedures in general surgery, including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy, gastric sleeve, small bowel resection, appendectomy, lysis of adhesions, fundoplication and hiatal hernia repair. Johnson & Johnson

Young women are leading a worrying increase in early-onset type 2 diabetes (T2D) diagnoses in England, according to a new analysis led by researchers from Imperial College London, UK. In a population study of T2D in England, the researchers found a clear generational divide, with diagnosis rates rising rapidly among younger adults, particularly women, while declining in older age groups. The research, published in Lancet Regional Health Europe, is the first to examine trends

The use of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes and obesity is associated with an increased risk of hair loss (alopecia) in adults with type 2 diabetes, a study published by The British Medical Journal (BMJ) has reported. Although the absolute risk is low, awareness of this potential effect may help inform shared treatment decisions, according to the study’s researchers from the University of Pennsylvania, Philadelphia, PA. Alopecia has b